Viatris Announces Launch of First Bioequivalent Generic Version …
https://ca.finance.yahoo.com/news/viatris-announces-launch-first-bioequivalent-105900014.html
WEBApr 15, 2024 · Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the launch in Canada of PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone® 20 mg/mL, indicated for the treatment of patients with Relapsing-Remitting Multiple Sclerosis (RMMS), a chronic inflammatory disease of the central nervous system.
DA: 19 PA: 98 MOZ Rank: 70